R&D Systems Inc. Tocris Bioscience Boston Biochem

Pifithrin-α hydrobromide

Cat. No. 1267

Pifithrin-a hydrobromide C16H18N2OS.HBr [63208-82-2]

Price and Availability

For Pifithrin-α hydrobromide pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 1-(4-Methylphenyl)-2-(4,5,6,7-tetra­hydro-2-imino-3(2H)-benzothiazolyl)ethanone hydrobromide

Biological Activity

Inhibitor of p53; reversibly blocks p53-dependent transcriptional activation and apoptosis. Protects against neuronal death in models of stroke and neurodegenerative disorders. Active in vivo; protects mice from the side-effects of cancer therapy associated with p53 induction. Supresses self-renewal of embryonic stem cells. Also aryl hydrocarbon receptor (AHR) agonist, causes upregulation of AHR target gene CYP1A1 (EC50 = 1.1 μM). Cyclic analog available (Cat. No. 3843).

Technical Data

M.Wt:
367.3
Formula:
C16H18N2OS.HBr
Solubility:
Soluble to 100 mM in DMSO
Storage:
Desiccate at -20°C
CAS No:
63208-82-2

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet

References

Komarov et al (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285 1733. PMID: 10481009.

Komarova and Gudkov (2000) Suppression of p53: a new approach to overcome side effects of antitumor therapy. Biochemistry 65 41. PMID: 10702639.

Culmsee et al (2001) A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid '-peptide. J.Neurochem. 77 220. PMID: 11279278.

Hoagland et al (2005) The p53 inhibitor pifithrin-α is a potent agonist of the aryl hydrocarbon receptor. J.Pharmacol.Exp.Ther. 314 603. PMID: 15843497.

Abdelalim and Tooyama (2012) The p53 inhibitor, pifithrin-α, suppresses self-renewal of embryonic stem cells. Biochem.Biophys.Res.Comm. 420 605. PMID: 22445757.

If you know of a relevant citation for this product please let us know.

Keywords: Pifithrin-a hydrobromide, supplier, p53, inhibitors, aryl, hydrocarbon, receptors, agonists, AHR, Transcription, Factors, Pifithrin-alpha, hydrobromide

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Guide

Request your free copy

Cancer Research Guide

Highlights over 350 products for cancer research. Request a copy or view PDF today.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

Checkpoint Kinases & the DNA Damage Response

Written by Michelle D. Garrett and Ian Collins

Cell Cycle Kinases Poster

A summary of the response of the checkpoint kinase signaling network to DNA damage, including activation of DNA repair, cell-cycle arrest, senescence and apoptosis.

divider line

The p53 Tumor Suppressor Response

Written by Christopher J. Brown et al

p53 Poster

A summary of the main strategies that may be utilized to reactivate p53 including several small molecules and peptides which act to stabilize p53 and rescue wild-type activity.

divider line

p53 Pathway

p53 Pathway

Signals through the p53 pathway are integral in the control of the cellular response different types of stress. View pathway or download PDF today.

divider line

New Product Guide

NPG

Highlights over 130 new products added in 2012. Request a copy or view PDF today.

divider line

New Products in this Area

Plumbagin

Induces G2/M cell cycle arrest; anticancer

Sign-up for new product e-alerts
divider line

20% Discount*

Potent, selective LRRK2 inhibitor

Potent LRRK2 inhibitor now available from Tocris Bioscience

Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.

* Terms & conditions